

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 August 2021 (26.08.2021)



(10) International Publication Number
WO 2021/168161 A1

(51) International Patent Classification:

A61K 38/13 (2006.01) A61P 11/00 (2006.01)
A61P 1/16 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/US2021/018639

(22) International Filing Date:

19 February 2021 (19.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/978,526 19 February 2020 (19.02.2020) US
62/981,383 25 February 2020 (25.02.2020) US

(71) Applicant: **HEPION PHARMACEUTICALS, INC.**
[US/US]; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US).

(72) Inventors: **URE, Daren, R.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US). **TREPANIER, Daniel, J.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US). **MAYO, Patrick, R.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US). **FOSTER, Robert, T.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US).

(74) Agent: **CHANG, Y., Paul**; Sheppard Mullin Richter & Hampton LLP, 12275 El Camino Real, Suite 100, San Diego, CA 92130 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF CYCLOSPORINE ANALOGUES FOR TREATING FIBROSIS




FIG. 1A

(57) Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*